The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma

Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAF(WT) and B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Simbulan-Rosenthal, Cynthia M., Dakshanamurthy, Sivanesan, Gaur, Anirudh, Chen, You-Shin, Fang, Hong-Bin, Abdussamad, Maryam, Zhou, Hengbo, Zapas, John, Calvert, Valerie, Petricoin, Emanuel F., Atkins, Michael B., Byers, Stephen W., Rosenthal, Dean S.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355037/
https://ncbi.nlm.nih.gov/pubmed/28157711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14990
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados